Abiomed announces fresh data from its USpella IRB registry of Impella 2.

Abiomed announces fresh data from its USpella IRB registry of Impella 2 http://tadalisx.com .5 patients Abiomed Inc. , a leading provider of breakthrough center support technologies, today announced new scientific data from USpella, the first U.S. Multicenter registry of Impella 2.5 individuals analyzing the feasibility and safety of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention and treatment of acute myocardial infarction . USpella, offered at TCT 2009 by Brijeshwar Maini, M.D., co-seat, cardiovascular research, interventional cardiologist, Pinnacle Wellness; attending cardiologist, Moffitt Center & Vascular Group, evaluated data from 16 Impella 2.5 centers with IRB acceptance and over 181 patients from the more than 1,000 reported commercial Impella 2.5 cases.